Raza Bokhari, Chief Executive Officer and Director of Medicus Pharma Ltd. (NASDAQ:MDCX), filed a Form 4 on November 17, 2026, disclosing the acquisition of 436,046 common shares on November 13, 2026, through an entity he controls.

Key Highlights

  • Acquisition date: November 13, 2026, via a subscription agreement entered into by RBx Capital, LP.
  • Shares acquired: 436,046 common shares, no par value, at a purchase price of $1.72 per share.
  • Transaction type: Code A (acquired) in a private placement in which other investors also participated under separate subscription agreements.
  • Post-transaction holdings: 451,909 common shares beneficially owned indirectly following the reported transaction.
  • Ownership structure: Shares are held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari; the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
  • Reporting person roles: Bokhari is identified in the filing as Director, 10% Owner, and Chief Executive Officer of Medicus Pharma Ltd.

RBx Capital Private Placement Details for Medicus Pharma

According to the Form 4 filed with the SEC, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with Medicus Pharma Ltd. on November 13, 2026. Under that agreement, RBx Capital, LP agreed to purchase 436,046 common shares, no par value, at a purchase price of $1.72 per share. The filing notes this transaction took place in a private placement in which other investors also participated under separate subscription agreements.

The filing reports that following the transaction, the indirect beneficial ownership held through RBx Capital, LP stands at 451,909 common shares. The reporting person disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, as stated in the filing's footnotes. The shares are classified as indirectly owned, with the nature of indirect beneficial ownership attributed to RBx Capital, LP.

Bokhari is identified in the filing as holding three roles in relation to the issuer: Director, 10% Owner, and Chief Executive Officer. The Form 4 was signed by Raza Bokhari and filed on November 17, 2026, covering the earliest transaction date of November 13, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing disclosed the acquisition of 436,046 common shares of Medicus Pharma Ltd. by RBx Capital, LP, an entity controlled by CEO Raza Bokhari, at $1.72 per share in a private placement on November 13, 2026, bringing indirect beneficial ownership to 451,909 shares.